Expanding Spectrum of Diseases Associated with Plasma Cell Dyscrasias

Similar documents
Interesting case seminar: Native kidneys Case Report:

Jo Abraham MD Division of Nephrology University of Utah

Forms Revision: Myeloma Changes

CASE 3 AN UNUSUAL CASE OF NEPHROTIC SYNDROME

Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT

Monoclonal Gammopathies and the Kidney. Tibor Nádasdy, MD The Ohio State University, Columbus, OH

Multiple Myeloma Advances for clinical pathologists & histopathologists

Pathology of Complement Mediated Renal Disease

Lec-14 د.خالد نافع. Medicine. Multiple Myeloma

Glomerular pathology in systemic disease

FIBRILLARY GLOMERULONEPHRITIS DIAGNOSTIC CRITERIA, PITFALLS, AND DIFFERENTIAL DIAGNOSIS

Sheena Surindran Grand Rounds 2/15/11

A Case of IgG2 Heavy Chain Deposition Disease in a Patient with Kappa Positive Plasma Cell Dyscrasia

Histopathology: Glomerulonephritis and other renal pathology

Multiple myeloma Biological & Clinical Aspects Isabelle Vande Broek, MD, PhD

Case Presentation Turki Al-Hussain, MD

Case Report A Case of Proliferative Glomerulonephritis with Monoclonal IgG Deposits That Showed Predominantly Membranous Features

Dr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust

Instructions for Plasma Cell Disorders (PCD) Post-HCT Data (Form 2116 Revision 3)

RENAL HISTOPATHOLOGY

Hematology 101. Rachid Baz, M.D. 5/16/2014

GRAND ROUNDS

Multiple intra-renal pathological injury patterns in resistant myeloma

Glomerular diseases with organized deposits

Serum free light chain (SFLC) assays. Dr Sarah Sasson SydPath Registrar

CASE 4 A RARE CASE OF INTRALUMINAL GLOMERULAR CAPILLARY DEPOSITS

Plasma cell myeloma (multiple myeloma)

Multiple Myeloma 101: Understanding Your Labs

Case 3. ACCME/Disclosure. Laboratory results. Clinical history 4/13/2016

M-Protien, what to do next? Ismail A Sharif MD, FRCPc Internal Medicine Day 22 nd April 2016

Hematology Case Conference 8/5/03

Overview of glomerular diseases

LIGHT CHAIN DISEASE B. DHANALAKSHMI 1 & V. HEMAVATHY 2

Serum Free Light Chain Assay

Clinical history. 73 yo man with chest pain Systemic hypertension and WG Stress EKG N Stress echocardiogram: Cardiac catheterization: no CAD

Anaemias and other Pesky Haematology Questions

A clinical syndrome, composed mainly of:

Case Report Nephrotic Syndrome Secondary to Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits of Lambda Light Chain

Mayo Clinic/ RPS Consensus Report on Classification, Diagnosis, and Reporting of Glomerulonephritis

Case Presentation Turki Al-Hussain, MD

Southern Derbyshire Shared Care Pathology Guidelines. MGUS (Monoclonal Gammopathy of Undetermined Significance)

Understanding the Serum Free Light Chain Assays. Anne L Sherwood, PhD Director of Scientific Affairs The Binding Site, Inc.

Complement in vasculitis and glomerulonephritis. Andy Rees Clinical Institute of Pathology Medical University of Vienna

Renal Pathology- Transplantation. Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic

Year 2004 Paper one: Questions supplied by Megan

Antibody-Cytokine- Autoimmune

RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST

Glomerular pathology-2 Nephritic syndrome. Dr. Nisreen Abu Shahin

Beta-2 microglobulin and short Ig chains and organ damage in dialysis patients: An update.

Glomerular diseases mostly presenting with Nephritic syndrome

C1q nephropathy the Diverse Disease

Monoclonal gammopathies consist of. Monoclonal GammopathyeAssociated Proliferative Glomerulonephritis REVIEW

Importancia del laboratorio en el seguimiento clínico de pacientes con mieloma múltiple

Ordering Physician. Collected REVISED REPORT. Performed. IgG IF, Renal MCR. Lambda IF, Renal MCR. C1q IF, Renal. MCR Albumin IF, Renal MCR

Disorders of the kidney. Urine analysis. Nephrotic and nephritic syndrome.

2016: Plasma Cell Disorders Pre-HCT Data

Malcolm P. McTaggart, PhD, 1 Jindriska Lindsay, FRCPath, 2 and Edward M. Kearney, FRCPath 1 ABSTRACT

Plasma Cell Disorders (PCD) Pre-HCT Data

Principles of Adaptive Immunity

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT MYELOMA CHAPTER 11C REVISED: SEPTEMBER 2016

Light-Chain Mediated Acute Tubular Interstitial Nephritis. A Poorly Recognized Pattern of Renal Disease in Patients With Plasma Cell Dyscrasia

Glomerular Pathology- 1 Nephrotic Syndrome. Dr. Nisreen Abu Shahin

WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia

Immunobiology 7. The Humoral Immune Response

Dr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust

Early View Article: Online published version of an accepted article before publication in the final form.

Szervusz [hi]everybody!

Classification of Glomerular Diseases and Defining Individual Glomerular Lesions: Developing International Consensus

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

RENAL EVENING SPECIALTY CONFERENCE

Approach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis

Jonathan Katz, MD CPMC

Case # 2 3/27/2017. Disclosure of Relevant Financial Relationships. Clinical history. Clinical history. Laboratory findings

C3 GLOMERULOPATHIES. Budapest Nephrology School Zoltan Laszik

Favorable effect of bortezomib in dense deposit disease associated with monoclonal gammopathy: a case report

CELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM.

Test Name Results Units Bio. Ref. Interval

CHAPTER 2. Primary Glomerulonephritis

Leicester. Research Group. Background. Inside. contact. Page 1: Background. Page 2-4: Leicester IgAN individual research

Plasma cell dyscrasia with renal impairment including MGRS

Nephrotic syndrome minimal change disease vs. IgA nephropathy. Hadar Meringer Internal medicine B Sheba

Elevated Serum Creatinine, a simplified approach

Case: The patient is a 73 year old woman with vague complaints of dyspepsia and abdominal pain. Upper endoscopy showed features of gastritis and a

Index. electron microscopy, 81 immunofluorescence microscopy, 80 light microscopy, 80 Amyloidosis clinical setting, 185 etiology/pathogenesis,

Renal Pathology 1: Glomerulus. With many thanks to Elizabeth Angus PhD for EM photographs

SUPPLEMENTARY APPENDIX

substance staining with IgG, C3 and IgA (trace) Linear deposition of IgG(+), IgA.M(trace) and C3(+++) at the DEJ

Case #1. Robert J. Glinert, M.D. David C. Fisher, M.D. Dana Farber Cancer Institute

Surgical Pathology Report

29th Annual Meeting of the Glomerular Disease Collaborative Network

Amyloid-like Pulmonary Nodules, Including Localized Light-Chain Deposition Clinicopathologic Analysis of Three Cases

Yijuan Sun, Amarpreet Sandhu, Darlene Gabaldon, Jonathan Danaraj, Karen S. Servilla, and Antonios H. Tzamaloukas

CORE CURRICULUM IN NEPHROLOGY Renal Manifestations of Plasma Cell Disorders

Diabetes. Albumin. Analyte Information

Laboratory Examination

Proteinuria (Protein in the Urine) Basics

IMMUNOBIOLOGY, BIOL 537 Exam # 2 Spring 1997

Immunology - Lecture 2 Adaptive Immune System 1

κ λ Antigen-Independent B-Cell Development Bone Marrow Ordered Rearrangement of Ig Genes During B-Cell Development in the Bone Marrow

ESRD Dialysis Prevalence - One Year Statistics

Transcription:

Expanding Spectrum of Diseases Associated with Plasma Cell Dyscrasias Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic eva.honsova@ikem.cz

Plasma cell dyscrasias Plasma cell dyscrasias represent a clonal expansion of abnormal plasma cells which produce a monoclonal protein that could be either the whole immunoglobulin (Ig) or a fragment of Ig (monoclonal free light or heavy chain in a variable quantity). LCs are removed from circulation by the kidneys, renal damage is a common complication and can by very heterogeneous.

Plasma cell function Normally plasma cells, and in lesser extent some type of B-cells, produce one of five heavy chain types (G, A, M, E, D), together with κ or λ molecules and create immunoglobulins After binding of the antigen ( ), a naive B cell is changed to a plasma cell Signal to the nucleus 2-3days After 10 days there will occur IgM Switch to produce IgG (2-3 weeks) and change to a memory cell Second contact with antigen: IgG almost immediately

Plasma cell dyscrasias Antibody molecules are composed of two identical heavy and light chains, each containing variable and constant domains. The variable domains - form an antigen-binding site, Light chains are of two types, κ and λ, and in any given antibody molecule only one type occurs.

Discovery of Bence-Jones protein: who is behid it? more than 150 years ago, the presence of Bence Jones protein was discovered the first in vitro cancer test Dr. Henry Bence Jones - In 1845, Dr William MacIntyre, a physician in London, was called to see a 45 year-old patient, - general practitioner, Dr Thomas Watson - Edema- possibility of nephrosis, he tested the urine for albumin - Both Dr MacIntyre and Dr Watson then sent urine samples to the Dr. Henry Bence Jones - The patient died, Dr MacIntyre subsequently published the post-mortem examination in 1850. - Henry Bence Jones had already described the patient s urinary findings in two, single-author articles (one in The Lancet, in 1847). - Bence Jones s reputation was assured, while the contributions of his colleagues a footnote in the history of medicine.

Discovery of Bence-Jones protein It had taken more than 100 years from the original observation than the features of Bence Jones protein were finally determined. Waldayer first identified - the protein originate in bone marrow plasma cells (1875). In 1922, Bayne-Jones and Wilson characterized two types of BJ protein (using antisera). The proteins were classified as group I and group II types. In 1956 Korngold and Lipari showed that antisera against the different groups also reacted with myeloma proteins. As a tribute to their observations the 2 types of BJ protein were designated: kappa and lambda. Edelman and Gally, in 1962, subsequently showed that FLCs prepared from IgG monoclonal proteins were the same as BJ protein.

Classification of monoclonal gammopathies, multiple myeloma (MM) and related disorders include following groups: 1.Monoclonal gammopathy of undetermined significance (MGUS) 2.Smouldering (asymptomatic) multiple myeloma 3.Symptomatic multiple myeloma 4.Nonsecretory multiple myeloma 5.Solitary plasmacytoma of bone 6.Extramedullary plasmacytoma 7.Multiple solitary plasmacytoma 8.Plasma cell leukaemia

Hematology classification & Several problems in daily practice nephropathology The clonal expansion of cluster of plasma cells is not only benign or malignant production of Igs or FLCs and these light chains can be deposited important facts were not incorporated in the classification schema MGUS and AL amyloidosis the term MG of renal significance The prevalence of plasma cell dyscrasias increases with advancing age Disorders associated with plasma cell dyscrasias often have NS or severe PU

The most frequent categories of renal diseases associated with MGUS and MM FLCs are nephrotoxic and can damage all kidney compartments: gli, tubuli and vessels. glomerulopathic FLCs 1. AL amyloidosis 2. LCDD 3. GN with monoclonal deposits tubulopathic FLCs 1. cast nephropathy 2. proximal tubulopathy 3. TIN associated with M protein + Combinations of the above diagnoses + Combinations with other diseases (hypertension, vascular nephrosclerosis, DM) Kidney involvement may represent the first manifestation of hematological disease.

AL amyloidosis The kidney is the most common organ involved in several types of systemic amyloidosis

Amyloidosis: detection of amyloid

Amyloidosis: diagnosis

Amyloidosis: typing IF is the best method for typing amyloid. It allows to classify more than 90% of amyloid in kidney biopsy samples.

Fascinating story of amyloidos Only a small number of patients with preconditions suffer from amyloidosis Per Westermark Comparison with prion diseases: change in the protein structure, conformational diseases Prion diseases are transmissible by food Amyloid enhancing factor (amyloid fibrils) Is amyloidosis transmissible? Yes, very probably Westermark GT, Westermark P. Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis. FEBS Lett. 2009;583:2685-2690. AA amyloidosis is transmissible in several animal experimental models AA amyloid can occur in human food (ducks, geese: pate de foie gras; cattle) AA amyloidosis is transmissible by blood monocytes

AL amyloidosis and LCDD Experimental works showed that LCs can transform the phenotype of mesangial cells. In cases of AL amyloidosis the phenotype evolves toward macrophages with development of lysosomes within which degradation and remodeling of LCs into amyloid occur. Amyloid deposition in the extracellular matrix results in activation of metalloproteinases followed by destruction of the native mesangial matrix. The normal mesangium is replaced by amyloid and mesangial cells disappear. In cases of LCDD, mesangial cells evolve into a myofibroblast phenotype, and mesangial cells proliferate under the influence of overproduction of TGF-β, resulting in the formation of mesangial nodules.

LCDD kappa

LCDD GBM DM!!! TBM

Proliferative GN with monoclonal deposits (IgG3 kappa) Mimics immune-complex GN (MPGN, MGN). Restriction of LC: IF positive is only kappa or less frequently only lambda IgG3 or IgG1 Proteinurie or NS, 50% have monoclonal protein in serum More frequent than LCDD (20 AL amyloidosis, 8 GN with monoclonal dep., 5 LCDD)

Proliferative GN with monoclonal deposits (IgG3 kappa) IgG IgG3 C3 C1q The key to the diagnosis: recognition of single light chain restriction

Proliferative GN with monoclonal deposits IgG3: greatest complement fixing ability Most positively charged subtype of IgG (can interact with negatively charged GBM) Highest MW (size restricted by glom. filter) Ability to self-aggregate spontaneously through Fc-Fc fragment interactions Monoclonal gamapaties can lead to proliferative GN via 2 mechanisms: 1. deposition of monoclonal Igs in the mesangium and along capillary walls activation of complement proliferative GN 2. monoclonal Igs cause the activation of alternative complement pathway by acting as autoantibodies (to complementregulating proteins) deposition of C3 (C3 GN) without Igs

Group II, tubulopathic light chains 1. cast nephropathy 2. proximal tubulopathy 3. TIN associated with M protein cast nephropathy (historically called myeloma kidney) was the first renal complication to be recognized in patients with myeloma Higher concentration of sodium changes the consistency of T-H protein from a fluid to the gel The development of the casts involves binding of T-H protein to the CDR3 region of Ig free LCs

Cast nephropathy (myeloma kidney) no guidelines for how many cast must be present in a biopsy sample

Proximal tubulopathy Two morphological patterns Kappa light chains IF remains the most sensitive method for the detection of LCs restriction

and many others: cryoglobulins, Waldenstrom GN, Lc crystal storage disease, ect.

Combined patterns Combined patterns of glomerulopathic and tubulopathic LCs injury (such as LCDD and LC cast nephropathy, amyloidosis and LC cast nephropathy) Because especially older patients suffer from plasma cell dyscrasias, differential diagnosis can be also more complicated by vascular diseases, DM and other glomerulopathies.

The diagnoses do not jump from the microscope???